Biotech Values

[nolo contendere]

Upon approval for 3rd line/T315I pos patients - many will actually use ponatinib in the second line to prevent the development of compound resistant mutations (2+ mutations 'in cis' or in same molecule). These are more likely to arise in patients who have seen multiple TKIs sequentially...

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1940237/

Regardless of marketing approval, I think this will quickly become de facto second line.